Advertisement

Pituitary

, Volume 4, Issue 3, pp 179–185 | Cite as

Successful Treatment of a Large Macroprolactinoma with Cabergoline During Pregnancy

  • Chienying Liu
  • J. Blake Tyrrell
Article

Abstract

We report a pregnant woman with a large macroprolactinoma successfully treated with cabergoline after a suboptimal response to bromocriptine. A 7 week pregnant woman with a history of a prolactinoma presented to the endocrine clinic with the complaints of headaches and nausea. She had a prolactin level of 65 µg/L 1/2 weeks following her last menstrual period. Bromocriptine was discontinued at 6 weeks gestation when pregnancy was confirmed. A PRL concentration was 1899 µg/L (non-pregnant normal range 1.39–24.20 µg/L, the mean peak levels during pregnancy reported from the literature are 200–210 µg/L) at 7 weeks gestation, and a repeat was 2197 µg/L. An MRI showed a 3 × 2.2 × 2.5 cm seller mass abutting the optic chiasm and displacing the optic nerves superiorly; the visual field testing was normal. Bromocriptine was reinitiated and the patient responded initially with decreasing headaches and declining PRL concentrations to 1488 µg/L at 15 weeks gestation. However, PRL increased to 1836 µg/L at 16 weeks and remained elevated despite bromocriptine 2.5 mg three times a day; in addition, she complained of severe nausea, vomiting, and persistent headaches. Cabergoline was added at 18 weeks gestation. PRL decreased dramatically from 1710 to 859 µg/L in 1 week, and to 488 µg/L within 4 weeks. A repeat MRI showed more than 30% reduction in tumor size. Bromocriptine was discontinued at 24 weeks gestation; she was maintained on cabergoline 0.5 mg twice a week without complaints. PRL levels ranged from 190 to 278 µg/L during the last 10 weeks of pregnancy. She had a C-section electively at 37 weeks gestation and delivered a healthy baby. Management options in this patient and during pregnancy are discussed.

prolactinoma pregnancy cabergoline bromocriptine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vician L, Shupnik MA, Gorski J. Effects of estrogen on primary ovine pituitary cell cultures: Stimulation of prolactin secretion, synthesis, and preprolactin messenger ribonucleic acid activity. Endocrinology 1979;104:736–743.Google Scholar
  2. 2.
    Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ. Pituitary gland growth during normal pregnancy: An in vivo study using magnetic resonance imaging.Am J Med 1988;85:217–220.Google Scholar
  3. 3.
    Elster AD, Sanders TG, Vines FS, Chen MYM. Size and shape of the pituitary gland during pregnancy and postpartum: Measurement with MR imaging. Radiology 1991;181:531–535.Google Scholar
  4. 4.
    Rigg LA, Lein A, Yen SS. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977;129:454–456.Google Scholar
  5. 5.
    Schenker JG, Ben-David M, Polishuk WZ. Prolactin in normal pregnancy: Relationship of maternal, fetal, and amniotic fluid levels. Am J Obstet Gynecol 1975;123:834–838.Google Scholar
  6. 6.
    Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972;113:14–20.Google Scholar
  7. 7.
    Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363–372.Google Scholar
  8. 8.
    Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1365–1370.Google Scholar
  9. 9.
    Katnznelson L, Klibanski A. Prolactin and its disorders. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. Philadelphia: JB Lippincott, 1995:444–654Google Scholar
  10. 10.
    Werder Kv, Fahlbusch R, Landgraf R, Pickardt CR, Rjosk HK, Scriba PC. Treatment of patients with prolactinomas. J Endocrinol Invest 1978;1:47–58.Google Scholar
  11. 11.
    Godo G, Koloszar S, Szilagyi I, Daru J, Sas M. Experience relating to pregnancy, lactation, and the after weaning condition of hyperprolactinemic patients treated with bromocriptine. Fertil Steril 1989;51:529–531.Google Scholar
  12. 12.
    Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y. Follow-up of children born of bromocriptine–treated mothers. Horm Res 1985;22:239–246.Google Scholar
  13. 13.
    Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertil Steril 1984;41:793–805.Google Scholar
  14. 14.
    de Wit W, Coelingh Bennink HJ, Gerards, LJ. Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: Report of 13 pregnancies. Br J Obstet Gynaecol 1984;91:1059–1069.Google Scholar
  15. 15.
    Mazze RI, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy:Aregistry study of 5405 cases. Am J Obstet Gynecol 1989;161:1178–1185.Google Scholar
  16. 16.
    Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 1992;38:84–89.Google Scholar
  17. 17.
    Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 1998;49:250–253.Google Scholar
  18. 18.
    Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 1994;331:904–909.Google Scholar
  19. 19.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.Google Scholar
  20. 20.
    Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.Google Scholar
  21. 21.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500–509.Google Scholar
  22. 22.
    Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333–337.Google Scholar
  23. 23.
    Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammorota T, Camanni M, Camanni F. Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumourous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997;20:547–551.Google Scholar
  24. 24.
    Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143–169.Google Scholar
  25. 25.
    Graven C, Ward K. Embryo, fetus, and plancenta: Normal and abnormal. In: Scott JR, Di Saia PJ, Hammond CB, Spellacy WN, eds. Danforth's Obstetrics and Gynecology. Philadelphia: Lippincott Williams & Wilkins, 1999:29–45.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Chienying Liu
    • 1
  • J. Blake Tyrrell
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of MedicineUniversity of CaliforniaSan Francisco, San Francisco

Personalised recommendations